产地：USA (美国)
存储条件：2-8
PDM 2009 H1N1（新型流感A）ValuPanel TM试剂*是LGC Biosearch Technologies的ValuPanel系列检测试剂的一部分。 ValuPanel试剂由鉴定不同病原菌株的探针和引物组成。这些新的PDM检测试剂被证明具有比原始2009年H1N1探针和引物更好的性能：这个更新的Panel对2009 H1N1具有更强的特异性和灵敏度。 *仅供研究使用。不用于诊断程序。 PDM 2009 H1N1鉴定获美国CDC许可** LGC Biosearch Technologies是一家授权的寡核苷酸制造商，其制造的寡核苷酸可用于2009 H1N1流行病的遗传鉴定。该Panel由双标记BHQ探针、正向引物和反向引物组成，用在实时定量PCR中以区分新型流感A H1N1与其他病毒株。PDM 2009 H1N1 ValuPanel试剂包含基于以下遗传鉴定的探针和引物： 通用流感A PDM流感A（猪流感特异性） PDM H1（猪流感特异性） 人类RNase P（提取对照） 这些探针用FAM和Black Hole Quencher（BHQ）染料标记。所有探针和引物经HPLC纯化。 LGC Biosearch是BHQ染料的发明者，是目前在标记探针中使用真正黑暗淬灭剂BHQ的制造商。 ** CDC不认可产品或服务 PDM 2009 H1N1与原始2009年H1N1 ValuPanel试剂有何区别？ 改进的特异性 - 新的探针和引物靶向在原始小组中解析的相同基因的更保守区域。因此，它们适用于检测在国际上出现的新型甲型流感H1N1的多种分离株，同时区分其他流感类型和菌株。 改进的灵敏度 - PDM 2009 H1N1 ValuPanel试剂被开发用于检测较少的新型流感病毒A的拷贝。 The PDM 2009 H1N1 (Novel Influenza A) ValuPanel™ Reagents* are part of LGC Biosearch Technologies’ ValuPanel line of detection reagents. ValuPanel Reagents are composed of probes and primers that resolve genetic signatures of different pathogen strains. These new PDM signatures demonstrate improved performance over the original 2009 H1N1 probes and primers: this updated panel targets the 2009 H1N1 with more specificity and sensitivity. *For Research Use Only. Not for use in diagnostic procedures. PDM 2009 H1N1 Signatures Licensed from the CDC** LGC Biosearch Technologies is a licensed manufacturer of oligonucleotides to resolve the genetic signatures of the 2009 H1N1 pandemic. This panel consists of dual-labeled BHQ® probes, a forward primer, and a reverse primer for use in real-time PCR to discriminate novel influenza A H1N1 from other viral strains. PDM 2009 H1N1 ValuPanel Reagents contain probes and primers based on the following genetic signatures: Universal Influenza A PDM Influenza A (Swine Flu Specific) PDM H1 (Swine Flu Specific) Human RNase P (Extraction Control) These probes are labeled with FAM and Black Hole Quencher® (BHQ®) dyes. All probes and primers are HPLC purified. LGC Biosearch is the inventor of the BHQ dyes and is the sole manufacturer of the true dark quencher currently used for the labeled probes in the 2009 H1N1 diagnostic test. **CDC does not endorse products or services How is PDM 2009 H1N1 Different than the Original 2009 H1N1 ValuPanel Reagents? Improved Specificity – the new probes and primers target more conserved regions of the same genes that were resolved in the original panel. They are therefore appropriate for detection of diverse isolates of Novel Influenza A H1N1 that emerged internationally, while discriminating against other flu types and strains. Improved Sensitivity – PDM 2009 H1N1 ValuPanel Reagents were developed for detection of fewer copies of Novel Influenza A.
Sequence information unavailable.